Menopausal and Postmenopausal Disorders Sleeping quality menopause climacteric progestin dydrogesterone micronized progesterone
Conditions
Interventions
1 mg 17 beta-
estradiol plus 100 mg micronized progesterone oral once a day for 3 months.,1mg 17 beta-
estradiol plus 10 mg dydrogesterone oral once a day for 3 months.
Experimental Drug,Experimental Drug
micronized progesterone,dydrogesterone
Sponsors
Faculty of medicine, Chiang Mai University
Reproductive medicine unit,
Obsterics and Gynecology department,
Maharaj Nakon Chiang Mai Hospital
Eligibility
Sex/Gender
Female
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: New menopausal patients at Maharaj Nakorn Chiang Mai Hospital suitable for estrogen plus progesterone treatment
Exclusion criteria
Exclusion criteria: contraindication for hormone replacement therapy recently use sleep drug recently use psychotic drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improving of sleeping quality (assessed by the PSQI score) Patient reported outcome using a questionnaire interview | — |
Secondary
| Measure | Time frame |
|---|---|
| The side effect and climacteric symptoms comparing between 2 arms. Patient reported outcome using a questionnaire interview | — |
Countries
Thailand
Contacts
Public ContactEkachai Leeangkoonsathian
Department of obstetrics and gynaecology, Maharaj Nakorn Chiang Mai Hospital
Outcome results
None listed